Frontier Dental Lab Group Partners with D&S Dental Laboratory

Frontier Dental Lab Group (“Frontier” or “FDL Group”) (www.frontierdentallabgroup.com), a leading dental laboratory platform, announced today that it has partnered with and made an investment in D&S Dental Laboratory, Inc. (“D&S”) (https://dnsdental.com/), a full-service dental laboratory based in Waunakee, WI.

Brent West, President of FDL Group, commented, “D&S has an extremely strong leadership team and culture which has resulted in its reputation as one of the top dental labs in the Midwest. We believe D&S will add immense value to the platform, and we could not be more excited to join forces with Steve Daggett, Peter Derauf, Don Statz, and Randy Stifter.”

Steve Daggett, Fixed Manager at D&S, commented, “On the verge of celebrating our 50th anniversary, we take tremendous pride in the growth and success D&S has experienced throughout the years. We are confident we have found the right partner in Frontier who can assist in taking our business to the next level, which will also benefit our valued employees, customers, and partners. We look forward to working with Brent, Gil, and the rest of the Frontier team and believe it is a great cultural fit.”

D&S is a full-service, NADL certified dental laboratory offering a wide range of dental restoration products spanning the crown and bridge, removable, implant, and orthodontic / sleep appliance categories. Headquartered in Waunakee, WI, D&S also has branches in Baraboo, WI, Eau Claire, WI, Greenfield, WI, and Rockford, IL, allowing it to offer local service that draws upon more than four decades of restorative dental experience.

Jimmy Frye, Vice President at O2, commented, “D&S has a rich history of nearly 50 years of excellence, and we could not be more thrilled to add them to the platform. Steve, Peter, Don, and Randy are phenomenal leaders who will be a great fit with the rest of the FDL Group team. Alongside NuArt, the partnership with D&S further strengthens the platforms Midwest presence.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”